E-LIB Suche - Ergebnisse für: Bachanova, V.

1

Phase 1 trial of Ruxolitinib combined with Nivolumab in pat..:

Bachanova, V. ; Zak, J. ; Cao, Q....
Hematological Oncology. 41 (2023) S2 - p. 582-582 , 2023

Link: https://doi.org/10.1002/..

2

Overall survival in classic Hodgkin lymphoma pts who progre..:

Desai, S. H. ; Spinner, M. ; Evens, A. M....
Hematological Oncology. 41 (2023) S2 - p. 366-368 , 2023

Link: https://doi.org/10.1002/..

3

Responses after Allogeneic NK Cell Therapy for Lymphoma: co..:

Bachanova, V. ; Cao, Q. ; Miller, J....
Hematological Oncology. 41 (2023) S2 - p. 518-519 , 2023

Link: https://doi.org/10.1002/..

4

Efficacy of brentuximab consolidation by metabolic response..:

Desai, S. H. ; Smith, A. ; Spinner, M....
Hematological Oncology. 41 (2023) S2 - p. 361-362 , 2023

Link: https://doi.org/10.1002/..

5

P618: SECOND-GENERATION CD19 TARGETING TRI-SPECIFIC KILLER ..:

Miller, J. ; Kodal, B. ; Hinderlie, P....
HemaSphere. 6 (2022) - p. 517-518 , 2022

Link: https://doi.org/10.1097/..

6

Neurotoxicity Outcomes Following Whole Brain Radiation Ther..:

Easwaran, T.P. ; Habib, A. ; Bachanova, V..
International Journal of Radiation Oncology*Biology*Physics. 114 (2022) 3 - p. e346-e347 , 2022

Link: https://doi.org/10.1016/..

7

S201: CAMIDANLUMAB TESIRINE: UPDATED EFFICACY AND SAFETY IN..:

Carlo-Stella, C. ; Ansell, S. ; Zinzani, P. L...
HemaSphere. 6 (2022) - p. 102-103 , 2022

Link: https://doi.org/10.1097/..

8

OLDER PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA..:

David, K. A. ; Sundaram, S. ; Kim, S.‐H....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

9

MAINTENANCE RITUXIMAB IS ASSOCIATED WITH IMPROVED OVERALL S..:

Hill, B.T. ; Switchenko, J.M. ; Martin, P....
Hematological Oncology. 37 (2019) S2 - p. 405-407 , 2019

Link: https://doi.org/10.1002/..

10

OUTCOMES FOR PATIENTS WITH MANTLE CELL LYMPHOMA EXPERIENCIN..:

Bond, D.A. ; Switchenko, J. ; Maddocks, K....
Hematological Oncology. 37 (2019) S2 - p. 408-410 , 2019

Link: https://doi.org/10.1002/..

11

INTRAVENOUS IMMUNOGLOBULIN THERAPY USE IN PATIENTS WITH REL..:

Jaeger, U. ; Tam, C. ; Borchmann, P....
Hematological Oncology. 37 (2019) S2 - p. 505-507 , 2019

Link: https://doi.org/10.1002/..

12

CORRELATIVE ANALYSES OF CYTOKINE RELEASE SYNDROME AND NEURO..:

Bachanova, V. ; Westin, J. ; Tam, C....
Hematological Oncology. 37 (2019) S2 - p. 308-310 , 2019

Link: https://doi.org/10.1002/..

13

GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19‐TARGETED THERAPY C..:

Schuster, S.J. ; Bishop, M.R. ; Tam, C....
Hematological Oncology. 35 (2017) S2 - p. 27-27 , 2017

Link: https://doi.org/10.1002/..

14

BEAM conditioning is well-tolerated and yields similar surv..:

Fair, C ; Shanley, R ; Rogosheske, J...
Bone Marrow Transplantation. 52 (2017) 3 - p. 491-493 , 2017

Link: https://doi.org/10.1038/..

15

Serum biomarkers TARC and IL‐6 predict relapse risk in Hodg..:

Bachanova, V. ; Trottier, B.J. ; Cao, Q...
Hematological Oncology. 35 (2017) S2 - p. 323-324 , 2017

Link: https://doi.org/10.1002/..